SecBot SecBot
SECBOTREPLAY Home › Report › CRMD

CRMD · CorMedix announced positive Phase III topline results from the ReSPECT…

CorMedix, Inc. · PRESS-RELEASE filed Apr 27, 2026 at 07:30 ET

At the news

BULLISHIMPACT 8/10

PRESS-RELEASE filed Apr 27, 2026 at 07:30 ET

CorMedix announced positive Phase III topline results from the ReSPECT trial, showing that rezafungin met the primary endpoint of non-inferiority vs. standard antimicrobial regimen in fungal-free survival at Day 90 for patients undergoing allogeneic HSCT. The drug demonstrated a favorable safety profile, particularly in reduced toxicity-related discontinuations and drug-drug interactions, supporting a potential sNDA submission in 2H26 for expanded prophylactic use.

  • ReSPECT Phase III trial met primary FDA/EMA endpoint: non-inferiority in fungal-free survival at Day 90 (60.7% for rezafungin vs. 59.0% for standard regimen).
  • Rezafungin showed favorable secondary outcomes in safety, including lower rates of treatment discontinuation due to adverse events and fewer drug-drug interactions.
  • sNDA submission to FDA expected in 2H26, following a pre-NDA meeting.
  • Rezafungin is already approved for candidemia and invasive candidiasis; this data supports expansion into prophylaxis, a potential $2B+ US market.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access